Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

Figure 1: Structures of drugs and mAb-drug conjugates. AE and MMAE are highly stable molecules. There were no signs of compound degradation after 16 d in buffered saline at 37 °C. Furthermore, there ...

Biopharmaceutics is a rapidly growing research field that aims at producing viable therapeutic and prophylactic treatments for many diseases. The use of biological therapies has increased ...

Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

The 3rd Next-Generation Conjugates Summit (Boston | February 26-28, 2024) is the only event dedicated to showcasing conjugate drugs with novel payloads and formats, providing unrivalled access to 30+ ...